How can you identify which patients may benefit from the addition of Daxas®?
Is your patient...
- Aged 40 years or over?
- Diagnosed with severe COPD?
- On maintenance treatment with inhaled drugs?
Does he or she have...
- A history of frequent exacerbations?
- Symptoms of chronic cough and sputum?
If you answered ‘yes’ to all of these questions, adding Daxas® may help to reduce exacerbations in this patient.
In particular, patients in group D who have chronic bronchitis in the GOLD classification (see section on Treating COPD) are likely to benefit from Daxas® treatment. According to this definition, such patients typically have severe/very severe airflow limitation and/or ≥2 exacerbations per year, in addition to dyspnoea (assessed by the Modified Medical Research Council Dyspnea Scale grade ≥2 or COPD Assessment Test score ≥10).1
1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2011. www.goldcopd.org